The effect of rituximab therapy on immunoglobulin levels in patients with …7thSpace Interactive (press release)Methods: We performed a single centre retrospective review of 177 patients with multisystem autoimmune disease receiving rituximab between …
|
Vaccines and Biologics: Questions Remain
MedPage Today Inadequate protection after influenza vaccination also has been seen among patients receiving the B-cell depleting agent rituximab (Rituxan), with particularly low responses being seen among patients whose B cells are fully depleted. Therefore, “it … |
Drug Discovery & Development |
EU Committee Backs Roche Leukemia Drug Combo
Drug Discovery & Development … without their disease worsening (progression free survival; PFS) compared to chlorambucil alone and compared to MabThera (rituximab) plus chlorambucil while also increasing the depth of remissions as measured by Minimal Residual Disease (MRD). |
Pharmazeutische Zeitung online |
Rituximab geht unter die Haut
Pharmazeutische Zeitung online Rituximab geht unter die Haut Der Antikörper Rituximab darf Lymphom-Patienten nun auch subkutan appliziert werden. Über die Zulassungserweiterung informiert Hersteller Roche in einer Pressemitteilung. Die Injektion unter die Haut dauert nur wenige … |
Liver uptake on PET predicted treatment response in mediastinal large B-cell …The Oncology ReportData source: Prospective cohort study of 115 adults with primary mediastinal large B-cell lymphoma who underwent PET and CT scans after treatment with ri…
Immunomedics Announces US Patent Issuance For IMMU-114 – Quick FactsRTT NewsMoreover, in one animal model of human NHL, treatment with the anti-HLA-DR antibody was more effective than rituximab in yielding 100% long-term survival. Click here to receive…
Genetic Engineering News |
Top 18 Best-Selling Drugs Launched in 2013
Genetic Engineering News Another new drug that could not make the list is Biogen Idec’s Gazyva (obinutuzumab), a next-generation version of Rituxan (rituximab) approved and launched last year. The company reported only a combined $1.1 billion in sales for both versions in 2013 … |
OncLiveTargeting CD19 May Yield Paradigm-Altering TechnologyOncLiveFor the past two decades, researchers have been exploring B-cell specific antigens in hopes of developing a new anticancer target that would mirror the success of the CD20-targeting rit…
Dr Valentin Goede: New anti CD-20 agent for the treatment of CLLMD-FM The first medical webradioCurrently, the anti-CD-20 monoclonal antibody rituximab is a standard of care for these patients. A second anti-CD-20 antibody, ofatumumab came out in 2012,…
Biologic agents do not up recurrent cancer risk in RAThe Oncology ReportThe hazard ratios, adjusted for age and sex, for recurrent cancer were 0.55 for patients treated with drugs directed at tumor necrosis factor (TNF)-alpha and 0.47 for patients trea…